Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

23.780
+0.3201.36%
Volume:1.36M
Turnover:32.36M
Market Cap:20.74B
PE:76.03
High:24.040
Open:23.800
Low:23.680
Close:23.460
52wk High:30.750
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.63
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.313
ROE:46.90%
ROA:-0.81%
PB:2.16
PE(LYR):76.03
PS:4.40

Loading ...

HUTCHMED (China) Limited (Stock Code: 13) Schedules 2025 Final Results Announcement and Board Meeting

Bulletin Express
·
Feb 06

HUTCHMED (China) Ltd. kündigt Veröffentlichung der finalen Geschäftszahlen an

Reuters
·
Feb 06

HUTCHMED to Announce 2025 Final Results

GlobeNewswire
·
Feb 06

BOCOM International Forecasts Continued Stable Growth for Healthcare Sector This Year, Recommends Seeking Undervalued Stocks

Stock News
·
Feb 05

HUTCHMED (China) Limited (00013) Publishes January 2026 Monthly Return

Bulletin Express
·
Feb 02

Hutchmed (00013) Rises Over 4% Again, Up More Than 20% This Month; SACHI Phase III Study Results Published in The Lancet

Stock News
·
Jan 16

HUTCHMED Surges Over 3% in Intraday Trading as SACHI Phase III Study Results Published in The Lancet

Deep News
·
Jan 15

HUTCHMED (00013) Announces Publication of SACHI Phase III Study Results in The Lancet

Stock News
·
Jan 14

HUTCHMED Reports Phase III SACHI Trial Success for Savolitinib and Osimertinib in Advanced NSCLC

Reuters
·
Jan 14

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

GlobeNewswire
·
Jan 14

Multiple Positive Catalysts Drive Five-Day Rally, Is HUTCHMED (00013) Turning Around After Missing the Bull Run?

Stock News
·
Jan 09

Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)

Stock News
·
Jan 08

HK Movers | Innovative Drug Stocks Jump With TYK Medicines up 14%

Tiger Newspress
·
Jan 07

HUTCHMED's Sovleplenib Meets Main Goal of Phase 3 Study

MT Newswires Live
·
Jan 07

HUTCHMED (00013) Announces Positive Top-Line Results from Phase III Stage of ESLIM-02 Study of Sovleplenib in Warm Antibody Autoimmune Hemolytic Anemia in China

Stock News
·
Jan 07

BRIEF-Hutchmed Announces Positive Topline Phase III Trial Of Sovleplenib For Warm Antibody Autoimmune Hemolytic Anemia

Reuters
·
Jan 07

HUTCHMED Announces Positive Topline Results of Phase Iii Part of Eslim-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

THOMSON REUTERS
·
Jan 07

HUTCHMED (China) Ltd - Phase Iii Trial of Sovleplenib Meets Primary Endpoint

THOMSON REUTERS
·
Jan 07

BofA Adjusts Price Target on HUTCHMED (China) to $22 From $25, Maintains Buy Rating

MT Newswires Live
·
Jan 06

HUTCHMED (00013) Initiates Phase III Stage of Ongoing Study of Surufatinib Combined with Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

Stock News
·
Jan 05